Egorova Vera S, Kolesova Ekaterina P, Lopus Manu, Yan Neng, Parodi Alessandro, Zamyatnin Andrey A
Scientific Center for Translation Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.
School of Biological Sciences, UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai Kalina Campus, Vidyanagari, Mumbai 400098, India.
Pharmaceutics. 2023 Jun 29;15(7):1848. doi: 10.3390/pharmaceutics15071848.
Cathepsin B is a lysosomal cysteine protease, contributing to vital cellular homeostatic processes including protein turnover, macroautophagy of damaged organelles, antigen presentation, and in the extracellular space, it takes part in tissue remodeling, prohormone processing, and activation. However, aberrant overexpression of cathepsin B and its enzymatic activity is associated with different pathological conditions, including cancer. Cathepsin B overexpression in tumor tissues makes this enzyme an important target for smart delivery systems, responsive to the activity of this enzyme. The generation of technologies which therapeutic effect is activated as a result of cathepsin B cleavage provides an opportunity for tumor-targeted therapy and controlled drug release. In this review, we summarized different technologies designed to improve current cancer treatments responsive to the activity of this enzyme that were shown to play a key role in disease progression and response to the treatment.
组织蛋白酶B是一种溶酶体半胱氨酸蛋白酶，参与重要的细胞稳态过程，包括蛋白质周转、受损细胞器的巨自噬、抗原呈递，并且在细胞外空间中，它参与组织重塑、激素原加工和激活。然而，组织蛋白酶B的异常过表达及其酶活性与包括癌症在内的不同病理状况相关。肿瘤组织中组织蛋白酶B的过表达使这种酶成为智能递送系统的重要靶点，该系统对这种酶的活性有反应。由于组织蛋白酶B切割而激活治疗效果的技术的产生为肿瘤靶向治疗和控释药物提供了机会。在这篇综述中，我们总结了旨在改善当前针对这种酶活性的癌症治疗的不同技术，这些技术已被证明在疾病进展和治疗反应中起关键作用。
